Feihe Balanced Scorecard
Fully Editable
Tailor To Your Needs In Excel Or Sheets
Professional Design
Trusted, Industry-Standard Templates
Pre-Built
For Quick And Efficient Use
No Expertise Is Needed
Easy To Follow
Explore the Complete Growth Strategy Behind the Preview
This Feihe Balanced Scorecard Analysis gives you a structured view of the company's financial, customer, internal process, and learning and growth priorities. The page already shows a real preview of the actual analysis, so you can review the content before buying. Purchase the full version to get the complete ready-to-use report.
Benefits
Vertical Synergy
Vertical synergy gives Feihe one control loop from pasture management to retail distribution, so the scorecard can track milk quality at every step. With a 100 percent self-owned supply chain, managers get real-time cost visibility across breeding, processing, and logistics, which helps protect margins. This tight integration also supports faster response to quality drift, supply shocks, and local demand changes, which matters for market leadership.
Premium Alignment
Premium Alignment ties FY2025 R&D spend to sales growth in super-premium lines like Astrobaby, so management can see whether product science turns into real revenue. It also tests if nutritional claims justify a price premium versus imported peers in tier-one cities, where small mix shifts can matter. If the premium line grows faster than the mass line, Feihe's R&D is paying back in both volume and margin.
Consumer Safety
Feihe's consumer safety scorecard should tie factory audit results to trust metrics like scan rates, complaint volume, and repeat purchase behavior. Its QR-code traceability lets millions of parents check batch origin and safety in seconds, so the control only matters if scan use stays high and audit gaps stay near zero.
That link turns safety from a process check into a measurable brand asset.
Retail Efficiency
Feihe's internal process controls support more than 100,000 retail points of sale across China's provinces, which helps keep store-level execution tight. By tracking sell-through, replenishment, and local demand swings, Feihe can tune regional inventory to fit each demographic pocket. That lowers stockouts and overstock, so milk formula reaches shelves when parents need it. It also helps protect sales in a market where demand can shift fast by city and province.
Talent Development
Feihe's talent development in the learning-and-growth perspective is tied to keeping expert scientists in breast milk research and pediatric nutrition, which protects its know-how against domestic rivals. By tracking the number and depth of specialized staff, Feihe can keep product claims, R&D speed, and patent-backed IP ahead through 2026. This matters because human capital is the main moat in infant nutrition, where formula quality and research credibility drive shelf trust.
Feihe's Self-Owned Supply Chain Drives Trust, Reach, and Margin
Feihe's benefits show up in tighter control, faster safety checks, and better margin protection: a 100 percent self-owned supply chain links pasture to shelf, while more than 100,000 retail points of sale support sharp local execution. QR traceability and premium-line R&D turn trust and product science into measurable sales and repeat buy gains.
| Benefit | FY2025 metric |
|---|---|
| Supply control | 100 percent self-owned chain |
| Market reach | 100,000+ retail POS |
What is included in the product
Detailed Word Document
Editable Excel File
Drawbacks
Birth Rate Bias
Feihe's volume targets can miss China's shrinking birth base: births were 9.54 million in 2024, down 5.7% year on year, after a long slide from 12.0 million in 2016. If management still plans off old demand curves, production quotas can overshoot real sell-through and lift storage, discounting, and write-off costs. In a market where infant formula demand is under pressure, birth-rate bias can quietly hurt margin and cash flow.
Implementation Complexity
Feihe's balanced scorecard is hard to run across a large, multi-site dairy network because each plant and pasture needs the same KPIs, cadence, and audit trail. That means higher IT and people costs, since dozens of sites can generate mismatched data fields and manual reconciliations. In 2025, that complexity can slow decisions and raise control risk across regional subsidiaries.
Rigidity Risk
Rigid KPIs can backfire when China's 2025 rules on infant nutrition and health claims keep shifting. Feihe may keep chasing infant-formula targets while missing the healthy-aging pool, which is already tied to China's 300 million-plus people aged 60 and over. That makes strategy slower to adapt, and it can leave new revenue on the table.
Innovation Lag
Feihe's innovation lag can come from a safety-first culture that rewards audit pass rates more than bold R&D. In 2025, that can push teams to polish existing formulas instead of testing bio-engineered ingredients for premium lines. The result is slower product refreshes, less white-space growth, and weaker pricing power versus faster-moving peers.
- Safety metrics can crowd out experimentation.
- Audit focus slows premium formula launches.
Market Gaps
Feihe's scorecard leans on high-end and super-premium sales, so it can miss demand in rural and lower-priced channels. That is a real gap in China, where lower-tier cities and county markets still account for a large share of formula volume, even as premium mix supports margin.
In FY2025, that bias can make growth look stronger than it is, because it tracks price-up, not reach-up. If Feihe does not measure value-tier penetration, it may underinvest in affordability and distribution where the next buyers are.
Feihe FY2025: Birth Slump and KPI Gaps Cloud Demand Visibility
Feihe's Balanced Scorecard can misread demand in FY2025 because China births fell to 9.54 million in 2024, down 5.7% YoY, so old volume targets can overstate sell-through. Multi-site controls also add cost and delay, as plant-level KPI gaps need manual fixes. Tight safety KPIs can slow R&D and premium launches, while a premium bias can miss lower-tier city demand.
| Risk | FY2025 signal |
|---|---|
| Demand miss | 9.54m births |
| Control load | More sites, more reconcile |
| Innovation lag | Safety over R&D |
| Channel gap | Lower-tier demand undertracked |
Full Version Awaits
Feihe Reference Sources
This is the actual Feihe Balanced Scorecard analysis document you'll receive upon purchase – no surprises, just a professional, ready-to-use report.
The preview below is taken directly from the full version, so what you see here is the same content you'll unlock after checkout.
Once purchased, you'll receive the complete Feihe Balanced Scorecard analysis in full detail, exactly as shown in this preview.
Frequently Asked Questions
Feihe uses the scorecard to monitor its goal of maintaining a 65 percent gross margin across its premium infant formula segments. By tracking net profit margins against the 15 percent marketing-to-revenue ratio, the company ensures that its significant brand spending translates into sustainable shareholder returns during the demographic shifts observed through early 2026.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site - including articles or product references - constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.